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Background: The main goal of anti-cancer therapy is to speciﬁcally inhibit the malignant activity of cancer cells,
while leaving healthy cells unaffected. As such, for every proposed therapy, it is important to keep in mind the
therapeutic index— the ratio of the toxic dose over the therapeutic dose. The use of immunotherapy has allowed
a means to both speciﬁcally block protein–protein interaction and deliver cytotoxic events to a tumor-speciﬁc
antigen.
Review scope: It is the objective of this review to give an overview on current immunotherapy treatment for can-
cers usingmonoclonal antibodies.We demonstrate three exciting targets for immunotherapy, TNF-α Converting
Enzyme (TACE), Cathepsin S and Urokinase Plasmogen Activator and go over the advances made with one of the
most used monoclonal antibodies in cancer therapy, Rituximab; as well as Herceptin, which is used for breast
cancer therapy. Furthermore, we touch on other venues of immunotherapy, such as adaptive cell transfer, the
use of nucleic acids and the use of dendritic cells. Finally,we summarize someongoing studies that spell tentative
advancements for anti-cancer immunotherapy.
General signiﬁcance: Immunotherapy is at the forefront of anti-cancer therapies, allying both a high degree of
speciﬁcity to general high effectiveness and fewer side-effects.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The 21st century has ushered in an era of great scientiﬁc progress
and discoveries, resulting in a surge of interest by the general public inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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not only in the eradication of disease, but also in extending the average
lifespan of humans. Unfortunately, as people live longer, new problems
arise. As age increases, an individual is more likely to develop complica-
tions, namely degenerative diseases, such as cancer.
In cancer biology, tumors are described as complex tissues
comprised of heterogeneous neoplastic cells interwoven with tumor-
associated stroma. The characterization of proteins associated with
tumors presents opportunities for targeted therapeutic intervention.
This approach is called “targeted therapy”. However, the heterogeneity
of tumors dictates that, in order to achieve successful clinical treatment,
it is necessary to employ a combination of targeted therapies. The most
speciﬁc targeted therapies currently in use are monoclonal antibodies.
In the last decade, the use of antibody therapy in the ﬁeld of oncolo-
gy has shown very promising results [1]. Due to their high speciﬁcity,
antibodies represent a promising method for interfering with a single
target molecule, with high selectivity. Back in 1980, the ﬁrst patient
with relapsed lymphoma was treated using a therapeutic antibody
approach. While the antibody was shown to be clinically ineffective,
the therapy was deemed innocuous and was well-tolerated [2,3].
These safety and tolerated rationales built up the groundwork that led
to the use of therapeutic antibodies in the treatment of cancer.
During the past few years, attention has turned to using antibodies
to target different tumor-associated antigens. These include surface
glycoproteins associated with clusters of differentiation, CTLA-A, or
pathways regulated by growth factors [4]. Furthermore, while the
use of monoclonal antibodies monotherapy has had a tremendous
impact on cancer treatment, namely in non-Hodgkin's lymphoma,
their efﬁciency has been further improved through the combination of
chemotherapy along with monoclonal antibodies [5].
However, many of the studies presented ambiguous or insufﬁcient
criteria for clinical objective response. Results from such studies may
improperly imply effectiveness when compared to historical controls.
This emphasizes the need for thoughtful changes in the application
of cancer treatment approaches, such as a combination of multi-
targeting antibody-based therapy [6–8].
2. Monoclonal antibody immunotherapy
One of themost promising and exciting ﬁelds inmodern anti-cancer
therapy involves the use of monoclonal antibodies which, once admin-
istered to the patient, will selectively and efﬁciently, target a particular
protein involved, in some way, with the proliferation of tumor cells. A
large number of monoclonal antibody therapies have already been
approved and are currently in use, as described in Table 1.
In the cases described below – TACE/ADAM17, Cathepsin S and
Urokinase Plasminogen Activator – the proteins show an abnormally
high expression in cancer cells. This makes them the perfect targets
for inhibition through the use of monoclonal antibodies.
Furthermore, we also take a look at Rituximab, one of the principal
antibodies used in anti-cancer therapy, as well as Herceptin, the
only antibody therapy approved by the FDA that targets the human
epidermal growth receptor 2 protein.Table 1
Monoclonal antibodies currently in use in anti-cancer immunotherapy, targets and respective c
the European Medicines Agency.
Adapted from Chames, P., et al. Br. J. Pharmacol, 2009 [9] and Oldham, R. K. and Dillman, R. O.
Monoclonal antibodies used in cancer immunotherapy
Generic name Commercial name Target C
Rituximab Rituxan CD20 N
Trastuzumab Herceptin Erb B2 (HER-2) B
Alemtuzumab Campath CD52 C
Cetuximab Erbitux EGFR C
Panitumumab Vectibis EGFR C
Bevacizumab Avastin VEGF C2.1. TNF-α Converting Enzyme (TACE)
Many growth factors and cytokines require proteolytic release
from the cell surface for their activation [11]. TNF-α converting
enzyme (TACE), also known as A Disintegrin and Metalloprotease 17
(ADAM17); is a transmembranemetalloprotease responsible for solubi-
lizing many pathologically signiﬁcant membrane substrates and is an
appealing therapeutic target for the treatment of several diseases [11].
In terms of structure, mature ADAM-family ectodomains contain a
globular metalloprotease catalytic domain, a disulﬁde-dependent
disintegrin-cysteine rich (Dis-Cys) domain and, in some cases, an
epidermal growth factor (EGF)-like domain [11].
Initially, TACE was described as an enzyme, whose function was
attributed to solubilizing membrane-associated pro-TNF-α [12] — a
process named “ectodomain shedding”. Since then, TACE has been
described as capable of cleaving epidermal growth factor receptor
(EGFR) ligands [13,14], extracellular Notch1 [15], adhesion molecules
[16] and cell-surface receptors [17]. Ever since proteolytic cleavage
has been proven to be indispensable for the activation of many of
these substrates, TACE has been studied as a target in the treatment of
cancer [18] and rheumatoid arthritis [19]. Furthermore, dysregulation
of ectodomain shedding has been linked to autoimmune and cardiovas-
cular diseases, neurodegeneration, infection and inﬂammation [20].
Several studies have demonstrated that TACE is over-expressed in
various tumor cells, such as those from ovarian cancer, breast cancer,
pancreatic ductal adenocarcinoma, colorectal carcinoma, gastric cancer
stem cells, gastrointestinal stromal tumors (GIST), non-small cell lung
carcinoma and head and neck cancer [21]. This protein has also been
associated in governing endothelial cell migration and pathological
angiogenesis, which are equally relevant to tumor growth [21]. Chemo-
therapy may activate TACE, leading to growth factor shedding, which
contributes to resistance in colorectal cancer models, as well as contrib-
uting to resistance to trastuzumab in breast cancer [21].
There is a very high homology (96%) between the human andmouse
TACE ectodomains, whichmakes the antibody selection and production
process even more important. Adding to that, there is the need to ad-
here to the therapeutic requirements for human antibodies and the de-
sire to avoid metzicin active site immunoreactivity. For these reasons,
antibody phage-display presents an attractive technology for producing
a speciﬁc TACE inhibitor [22].
Antibody phage-display is a powerful in vitro selection technology
capable of producing fully human antibodies against human antigens.
A ﬂowchart of the main steps in phage-display technology is present
in Fig. 1.
This technique can be used to direct antibodies towards desired epi-
topes, due to the biochemical control available during selection condi-
tions. Solution-phase phage display typically produces antibodies with
non-linear (conformational) epitopes. Thus, intricate macromolecular
cross-domain binding might be hypothetically achieved through this
technology, an ideal scenario for an ADAM inhibitor [11]. In fact, anti-
bodies have been produced through phage display, due to recent tech-
nical advances, capable of recognizing multiple distinct antigens [23]
and different conformations of the same antigen [24,25].ancer types, as well as date of approval both by the Food and Drink Administration and by
Journal of Clinical Oncology, 2008 [10].
ancer type FDA approval EMEA approval
on-Hodgkin's lymphoma 26/11/1997 2/6/1998
reast 25/9/1998 28/8/2000
hronic lymphocytic leukemia 7/5/2001 6/7/2001
olorectal 12/2/2004 29/6/2004
olorectal 27/9/2006 19/12/2007
olorectal 26/2/2004 12/1/2005
Fig. 1. Flowchart for theprotocol for PhageDisplay Technology. VL andVH refer to variable light and variable heavy chains in antibodies. Various genes responsible for encoding the variable
regions of antibodies are ampliﬁed fromhuman B-cells and used to build an antibody library. The library is cloned for display on the surface of the phage. In a procedure similar to the two-
hybrid system, the antibody fragment is expressed in fusionwith the virus coat protein. The phage display library goes through a process of selection,whereupon those that do not bind to
the selected epitopes arewashed away. The ones that do are eluted and ampliﬁed by infection of Escherichia coli. After an adequate number of selection series, the speciﬁcity of the desired
antibody can be assessed through Enzyme-Linked Immunosorbent Assay (ELISA) or Fluorescent-Activated Cell Sorting (FACS). Once the achieved speciﬁcity is satisfactory, the genes
corresponding to the antibody's variable regions can be cloned into whole human IgG expression vectors and transfected into cells, such as HEK293, which will produce fully human
mAbs (hmAbs). The antibodies will be expressed into the cell medium. At that point, the supernatant can be collected for antibody puriﬁcation.
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phage-display, which targets the TACE ectodomain. Studies have
allowed a comprehensive understanding of the biochemical properties
of D1(A12), through the use of assays on human cancer cells. Further-
more, it has been conﬁrmed through xenograft analyses, in in vitro as
well as in vivo, that D1(A12) serves as a potent inhibitor of human
ADAM17's activity [11,21]. However, later studies have demonstrated
that this antibody was unable to lower the concentration of human
TNF-α circulating in the bloodstream. These results suggest that, follow-
ing the inhibition of ADAM17 in an in vivo environment, other factors
may replace the concentration of TNF-α [21]. One possible culprit is
ADAM10, as this enzyme has shown sheddase activity towards TNF-α
in murine ﬁbroblasts that were deﬁcient in ADAM17. In certain types
of lymphoma, ADAM10 is also responsible for the solubilization of
TNF-α [21]. Recently, it was determined that the D1(A12) antibody
can successfully inhibit the proliferation and motility of cancer cells in
head andneck squamous cell carcinoma (HNSCC), by reducing the over-
all amount of circulating EGFR ligands [26]. These results further prove,
not only the promising future applications of this particular antibody in
cancer therapy, but also the importance of cancer immunotherapy,
moving forward.
Studies continued, in an effort to identify an antibody possessing
cross-reactivity between human andmouse antigens. This is important,
particularly in pre-clinical trial conditions, to ensure the safety of the
proposed therapy. Thus, a method was proposed that alternates
selection rounds between human andmouse antigens [22]. The discov-
ery of such an antibody would allow research to proceed into a purely
in vivo environment. With these conditions in mind, work continued,
resulting in the identiﬁcation of A9, an antibody clone that demonstrat-
ed mostly non-competitive inhibition [22].
Subsequent experiments revealed that A9was anallosteric inhibitor,
which could bind to a secondary site outside the catalytic cleft of
TACE, thus disturbing its ability to bind to the active site [22]. In fact,
experiments developed in the presence of CT1746 – a hydroxamate
inhibitor of metalloproteinases that interacts with TACE's active site
Zn [26] – demonstrated that the binding of ligands to the active site of
TACE affected the A9 binding site on the protein. In other words, the
afﬁnity of A9 to TACE was reduced in the presence of CT1746 [22].
This data suggests that the inhibition of TACE by A9 is not purely non-
competitive, but rather a mixed form of inhibition.
It is important to consider that there are approximately 70 known
metzincin metalloproteases that possess Zn in their active site [27].
Therein lies the problem of small molecule inhibitors of TACE: the lack
of selectivity in these inhibitors would lead to off-target toxicity [28].
Hence, the signiﬁcance of A9: a non-Zn-binding inhibitor, speciﬁc for
the TACE protein.
Due to the importance of this protein in a cancer environment and
the promising results described above, this area and, in particular,
TACE inhibition; has proven itself to be rife with possibilities on the
path of cancer research and eventual eradication.
2.2. Cathepsin S
Another promising target being investigated is Cathepsin S, a proteo-
lytic enzyme. This protein functionspredominantly as anendopeptidase
within the endolysosomal vesicles of healthy cells, and is involved in
many physiological processes, such as differentiation, protein turnover,
degradation and apoptosis. In many cancer cell lines, Cathepsin S has
been demonstrated to be highly expressed or upregulated, contributing
to the development and progression of the cancer phenotype [6].
In colorectal cancer patients, Cathepsin S associates with the cell
membrane, providing an opportunity for antibody-dependent cellular
cytotoxicity. In fact, the targeting of Cathepsin S, in this case, through
the use of a humanized antibody with an immune effector function,
has resulted in natural killer cell targeted tumor killing, with a 22% cyto-
toxic effect [29,30]. Furthermore, by selectively targeting Cathepsin S,the antibody treatment inhibits the breakdown of the extracellular
membrane around the extracellular periphery of tumor cells, resulting
in the attenuation of tumor cell invasion through the extracellular
membrane. This leads to an inhibition of tumor cell invasion, growth
and neovascularization [29].
A recent antibody, Fsn0503h, has been developed which can
inhibit Cathepsin S. The in vivo results are promising, and include the
suppression of angiogenesis and metastasis, effectively halting cancer
progression. While there is still much to be uncovered regarding this
lysosomal cysteine protease, Cathepsin S is thought to contribute to
resistance against more common types of cancer therapy, such as
radio and chemotherapies, making it an important research subject in
the ﬁeld of immunotherapy [34].
2.3. Urokinase Plasminogen Activator
Mammary carcinoma and lung cancer are the most common type of
malignant tumors in adult women and an undeniable concern for gen-
eral public health. Unfortunately, some of the issueswith ﬁnding a solu-
tion to human breast cancer include its high genetic heterogeneity,
different molecular proﬁles and varied clinical behavior. One of the
targets being focused on, in an attempt to eradicate this type of tumor,
is the urokinase plasminogen activator protein [31].
The urokinase plasminogen activator (uPA) system is composed of
uPA, a speciﬁc cell receptor for uPA (uPAR), and serpin inhibitors of
uPA, such as plasminogen activator inhibitor-1. Among the roles of
this system, are the release and processing of latent growth factors
located on the extracellular membrane, such as FGF-2, VEGF, HGF and
TGF-β. There is a great number of papers describing the crucial role of
uPAR in the evolution of some solid cancers, including breast, colon,
prostate, pancreatic, ovarian, lung and brain, as well as several hemato-
logic malignancies such as acute leukemia and myeloma [31,32]. This
has led to the recent identiﬁcation and development of a monoclonal
antibody that speciﬁcally targets uPAR. This therapy has proven effec-
tive in a number of different animal tumor models, without blocking
the interaction between uPA and uPAR [32].
Recently, a novel therapeutic uPAR antibody was developed, ATN-
658, which has been capable of exhibiting reliable anti-tumor effects
across a variety of tumor models. ATN-658 has been proven to inhibit
invasion,metastasis and tumor proliferation aswell as induce apoptosis.
In uPAR's DIII domain, there is a small 6-mer disulﬁde loop near the gly-
colipid anchor, which serves as the antibody's epitope. The antibody
closely mimics the interaction of CD11b. CD11b-positive cells act as
suppressors to diminish cytotoxic T-cell response, allowing tumors to
progress, as well as secrete factors that drive that development.
ATN-658 blocks the CD11b–uPAR interaction, which leads to the
hypothesis that uPARmay actually function to promotemetastasis [32].
Beyond the use of antibodies, a study has been described that uses
aptamers, speciﬁcally RNA aptamers, which selectively bind to human
uPA, by targeting the active site of the enzyme. This inhibition effective-
ly halts the activation cascade of pro-uPA,while not interferingwith any
uPA that are already active, or even other serine proteases. The effects of
using the above aptamer, named upanap-126, include a reduction in
tumor dissemination and cell invasion [37].
As a result, the further study of the uPA systemmay be an important
future endeavor in the ﬁght against cancer.
2.4. Rituximab
One of the existing anti-cancer therapies that has found some
success, is the monoclonal antibody Rituximab.
Rituximab, also known as IDEC-C2B8 [33], is used for treatment
directed against the B-cell-speciﬁc antigen CD20 expressed on non-
Hodgkin's lymphomas. It revolutionized the clinical treatment of B-cell
non-Hodgkin's lymphoma, being the ﬁrst monoclonal antibody drug
to be approved, in 1997 [34]. It is a chimeric human–mousemonoclonal
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normal and tumor B-cells [33,34]. As CD20 is absent fromhematopoietic
stem cells, normal B-cells are able to regenerate after the Rituximab
treatment and return to pretreatment levels within several months or
years [35].
However, treatment with Rituximab has been linked tomoderate to
severe ﬁrst-dose side-effects, notably in patients with high numbers of
circulating tumor cells [36]. These side-effects include fever, rigors,
bronchospasm and hypoxemia, concomitant with rapid reduction and
laboratory evidence of tumor destruction [37]. In some cases, tumor
lysis syndrome has been detected in the 24 h period following the ﬁrst
infusionwith the antibody. This condition is characterized by a rapid re-
duction of the tumor followed by acute renal failure, hyperkalemia, hy-
peruricemia, hyperphosphatemia, hypocalcemia and, on occasion,
death. Other risks include a high number of circulating malignant cells
or high tumor burden. Should tumor lysis occur, electrolyte imbalances
should be corrected while monitoring renal functions and ﬂuid balance
[38].
When considering patients with autoimmune diseases, it is
important to keep in mind the unknown, but possible development of
malignancies with the administration of Rituximab. This is especially
compounded in elderly patients, as the recovery to normal levels of
B-cells can be delayed. Prolonged immunosuppression has been
associated with increased incidence of cancer [39]. Even so, the use of
Rituximab in autoimmune diseases is rapidly increasing [40]. While
the efﬁcacy and safety vary among different autoimmune diseases, the
use of this treatment is ultimately beneﬁcial, as is suggested by most
studies [39].
In cases of idiopathic neuromyelitis optica, a demyelinating disease
of the central nervous system characterized by the co-occurrence
of transverse myelitis and optic neuritis, treatment with Rituximab
was well tolerated and patients experienced less exacerbation than
expected, based on their historical data for attack rates [41]. In the
case of 35-year old woman, who had developed Burkitt's lymphoma
during early pregnancy, treatment with Rituximab and CHOP therapy
was safely administered, without causing any malformation, develop-
mental retardationor immunedysfunction in the child,while producing
complete remission in the mother [42].
It has been suggested that complement and complement inhibitors
are likely to play a role in the heterogeneity of the response to Rituxi-
mab in vivo [43]. Administration of Rituximab results in a prompt activa-
tion of the complement system, resulting in cytokine release. This, in
turn, activatesmacrophages andmast cells, which are capable of releas-
ing cytokines themselves as well as complement activation products,
which can function as anaphylatoxins, and might be thus responsible
for some of the side-effects [36]. It is likely that themechanismof action
of Rituximab in vivo is to some extent affected by the complement.
This means that studies to improve the safety as well as the efﬁcacy of
these treatments should keep in mind the role of the complement in
the treatment [36,44].
2.5. Herceptin
However, Rituximab is not the onlymonoclonal antibody therapy in
use today.
In 20% to 25% of invasive breast cancers, the human epidermal
growth receptor 2 protein (HER-2) has been found to be overexpressed
[45,46]. HER-2 is a tyrosine kinase that is related to the epidermal
growth factor receptor EGFR [45]. Its structure is composed of an extra-
cellular domain, a transmembrane domain and an intracellular domain
with tyrosine kinase activity [46]. This protein has the ability to trans-
form normal ﬁbroblasts and, when overexpressed, produce breast
cancer in transgenic mice. This enzyme has become an important
therapeutic target in breast cancer, as higher levels are closely linked
with higher pathogenesis and worse prognosis of breast cancer. Due
to the fact that HER-2 is overexpressed mainly in tumor cells, the riskof toxicity of HER-2 targeting drugs is decreased, as it is present in
much higher proportion in said tumor cells, compared to healthy cells
[45].
Herceptin, also known as trastuzumab, is a recombinant humanized
monoclonal antibody, directed against the extracellular domain of the
HER-2 protein. Currently, Herceptin is the only therapy approved by
the United States Food and Drug Administration that targets HER-2. Be-
fore treatment with this mAb therapy, the American Society of Clinical
Oncology recommends the evaluation of HER-2 status in all primary
breast tumor, both at the time of diagnosis and upon recurrence, as
this affords both prognosis information, as well as being determinant
of the response to Herceptin [45].
Although the exact mechanisms by which Herceptin is capable of
inhibiting HER-2 are not yet completely understood, some of its effects
have been observed, both in vitro and in vivo, such as diminished recep-
tor signaling, induction of apoptosis, inhibition of angiogenesis and inhi-
bition of DNA repair [45].
Someof themechanisms thatmay be used by therapeutic antibodies
to combat cancer cells are exempliﬁed in Fig. 2.
Initial phase I clinical trials with this antibody proved it to be safe
and with reliable pharmacokinetics, giving response rates of up to
34%. A later study observed that combining Herceptin with doxorubicin
plus cyclophosphamide produced longer time to progression, higher
response rates and improved survival rather, as opposed to simple
chemotherapy. However, this also caused severe cardiac dysfunction
[48]. At the same time, research groups are attempting to identify
new means of increasing Herceptin efﬁciency while decreasing
cardiotoxicity. The solution might include a multidisciplinary care
approach, with both cardiology and oncology specialists providing
a risk–beneﬁt assessment and proper patient education on how
to manage the disease, the cure and on adopting a healthy lifestyle
[49].
One of the main issues with this mAb therapy lies in the fact that
objective response rates, when in a monotherapy regimen, are low,
ranging from 12% to 34% for a duration of 9 months. Because of this,
Herceptin is usually administered in combinationwith chemotherapies,
such as paclitaxel or docetaxel, which increase response rates, time to
disease progression and overall survival [50]. Unfortunately, patients
who demonstrate an initial response to Herceptin-based regimens,
generally acquire resistance within one year [45].
Some mechanisms have been proposed that explain how tumors
avoid the cytotoxicity caused by this therapy. One such possibility are
mutations in the her2 gene (also called erbB-2), – which encodes for
the HER-2 protein – resulting in an inability for the antibody to recog-
nize its epitope and, therefore, to bind to HER-2 [45,51]. Another mech-
anism revolves around the fact that EGFR type I growth factor receptor
tyrosine kinase family consists of EGFR, HER-2, HER-3 and HER-4.
Although it is possible that Herceptin is, indeed, inhibiting cell signaling
through HER-2 binding, it will not reduce signaling through the other
HER receptors. Fortunately, new antibody therapies are being devel-
oped to counter this mechanism [45].
Moving forward, more research is being done with Herceptin in
order to maximize its potential as an immunotherapy. This includes
combining Herceptin with novel agents, such as the anti-EGFR tyrosine
kinase inhibitor gentiﬁbin, which has produced complete remission of
BT474 breast tumor xenograft; as well as developing novel strategies
for targeting HER-2, like the recombinant humanized HER-2 mAb
pertuzumab, capable of blocking the dimerization of HER-2 with
other HER receptors, thus avoiding one of the mechanisms described
above through which patients develop resistance to Herceptin therapy
[45].
Upon observing how much effort is being placed into ensuring
the effectiveness of anti-HER based treatment, it is clear that this mAb
therapy may have lost the battle, but is still far from losing the war.
This is especially true if new active targeted agents are developed,
namely against other members of the HER receptor family [51].
Fig. 2. Direct tumor cell killing by antibodies. This event may occur through receptor antagonist activity, which occurs when an antibody blocks dimerization, downstream signaling and
kinase activation, resulting in inhibition of proliferation and, ﬁnally, apoptosis (such is the case with TACE/ADAM17 binding and the therapeutic antibody Herceptin). It can also be
triggered by antibodies binding to a tumor cell surface receptor, leading to its activation and, consequently, apoptosis; which is represented by the mitochondrion. Finally, an antibody
may bind to an enzyme, leading to signaling abrogation, neutralization and cell death. Conjugated antibody therapies are based around delivering a payload – for example, a drug,
toxin, small interfering RNA or radioisotope – to a tumor cell.
Adapted from Scott, A. M. Nature Reviews Cancer, 2012 [47].
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However, Rituximab is not the only antibody currently being used or
studied for therapy. Other targets and antibodies are being considered
for therapeutic purposes.
One such case of a promising antibody is BMS-936558, also known
asMDX-1106 andONO-4538. This is amonoclonal antibody that targets
a key immune-checkpoint receptor expressed by activated T-cells, pro-
grammeddeath 1 (PD-1). PD-1 functionsprimarily in peripheral tissues,
where T-cells may encounter the immunosuppressive PD-1 ligands
PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed by tumor
cells, stromal cells or both. Inhibition of the interaction between PD-1
and PD-L1 can enhance T-cell responses in vitro andmediate preclinical
antitumor activity [52]. While the use of BMS-936558 was safe and
well-tolerated, results on its effectiveness are still inconclusive [53,54].
Other therapeutic targets include Glypican-3, claudins and the B-cell
maturation antigen.
Glypican-3 (GPC) is a member of the glypican family of heparan sul-
fate proteoglycans. It has presented itself as an attractive target for im-
munotherapy due to its overexpression in 72%–81% of hepatocellular
carcinoma (HCC), the leading cause of cancer-related deaths world-
wide. In these cases, immunotherapy has not had dramatic effects in
patients with advanced HCC, suggesting that further analysis and
knowledge of GPC3 biology are needed to allow the development of
more effective GPC3-targeted cancer therapies. Research has entered
clinical trials [55].
Claudins are tight junction proteins that are abnormally regulated in
several human cancers. In particular, claudin-3 and claudin-4 are fre-
quently overexpressed in several neoplasias, including ovarian, breast,
pancreatic, and prostate cancers. Even though tight junction proteins
have been studied for their role in tumorigenesis for many years, serial
analysis of gene expression (SAGE) and array analyses of breast and
ovarian cancers have identiﬁed claudins as proteins frequently alteredin cancer. These ﬁndings suggest a possible avenue for the detection,
diagnosis and treatment of drug-resistant cancers [56].
Multiple myeloma is a neoplasm of plasma cells and it affects 1 to 5
per 100,000 individuals worldwide, with a higher incidence in theWest
[57]. Although there is nomonoclonal-based targeted therapy approved
to treat patients with multiple myeloma. However, a monoclonal anti-
body therapy is being developed that selectively targets the B-cell
maturation antigen (BMCA), a member of the tumor necrosis factor
receptor superfamily. Conjugation of this anti-BMCA mAb J6M0 to the
potent microtubule disrupting monomethyl auristan E (MMAE) or F
(MMAF) with protease cleavable valine-citrulline (vc) or uncleavable
maleimidocaproyl (mc) linkers has yielded promising results. Particu-
larly, J6M0-mcMMAF (GSK2857916) has shown rapid and sustained
elimination of MM tumors in 3 different mice models, as well as induc-
ing antibody dependent cell mediated cytotoxicity (ADCC) and anti-
body dependent cell phagocytosis (ADCP) [58].
3. Other forms of immunotherapy
Although monoclonal antibodies are at the forefront of immuno-
therapy, particularly due to their effectiveness and speciﬁcity, along
with their safety of use; they are not the only forms of immunotherapy
being investigated and applied. Below, we offer brief compendiums on
each of the most prevalent immunotherapies available, which include
adoptive cell transfer, and the use of nucleic acids and dendritic cells.
3.1. Adoptive cell transfer
Adoptive cell transfer refers to the stimulation of T-cells ex vivo by
activating and expanding analogous tumor-reactive T-cell populations
to large numbers of cells that can then be transferred back to the patient,
or to a new recipient host,with the goal of transferring the immunologic
functionality and characteristics into the new host [59].
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through the use of peripheral blood mononuclear cells with tumor-
associated antigen. These antigen-presenting cells, such as dendritic
cells express certain cytokines, including interleukin-2, IL-7, IL-12,
IL-15 and IL-21 [60].
Combining immunotherapy with either cytotoxic chemotherapy or
targeted therapy can promote the therapeutic potential for the treat-
ment of cancers in comparison with the use of either treatment alone
[60]. Dying tumor cells release abundant antigen, whichmay induce cy-
totoxic chemotherapeutical agents to an increased effector cell capacity,
to recognize and kill tumor cells [61]. The processing of the antigens that
result from this event can lead to the priming of adoptively transferred
cells, as well as the activation of endogenous tumor-speciﬁc T cells [60].
Combined with chemotherapy, this treatment can lead to the enhance-
ment of anti-tumor immunity through increased tumor-speciﬁc
immune responses via the cross-priming of apoptotic tumor cell death
and shows to be beneﬁcial for survival in a phase II trial in patients
with newly diagnosed glioblastomas [62,63].
3.2. Nucleic acids
Recently, attention has turned to using nucleic acids directly. The
therapies developed center around protocols that include utilizing
small double-stranded RNA as an anti-tumor and anti-metastatic
solution. Small interfering RNAs have been documented as inducing
INF-α, but not proinﬂammatory cytokines, such as IL-6. Not only that,
but sdsRNA has also induced the secretion of TNF-α, in cases of hepato-
cellular carcinoma. As such, it is considered a potential adjuvant for the
therapy of immunosuppressive oncological diseases [64].
3.3. Dendritic cells
Dendritic cells are called the sentinels of the immune system. They
are crucial in the activation of antigen-speciﬁc immune responses,
such as naive T cells [65]. The ﬁeld of cancer immunotherapy has
been invigorated by the discovery that the vaccination with dendritic
cells loaded with tumor antigens is a potent strategy to elicit protective
immunity in tumor-bearing animal [66]. Dendritic cell therapy has im-
provedmuch since it was ﬁrst implemented, leading to an optimization
that aims to induce a strong and broad immune response in terms of the
recognized epitopes by both CD8+ and CD4+ T cells and the use of the
patient's complete and unique set of the human leukocyte antigen,
over the activation of humoral immunity [66,67].
This makes the choice of a particular tumor antigen with which
to load the dendritic cells an important starting point in this type of
therapy. The issues involved in this decision include the composition
of the antigen, namely whether it is a deﬁned tumor antigen or an
unfractioned mixture of tumor-derived antigens; and the form in
which the antigen should be presented, whether as a polypeptide or a
nucleic acid [66]. The use of nucleic acid templates for the expression
of tumor-derived antigens allows for the expression of the antigens as
full-length proteins within dendritic cells. This, in turn, permits the
patient's dendritic cells to display the peptides on their surface. On the
other hand, vaccine strategies based on synthetic peptides or proteins
require knowledge of the relevant peptides. Furthermore, the treatment
is only suitable for a select group of patients with a matching human
leucocyte agent type, often exclusively HLA-A2+ [66,67].
Although DC-based cancer vaccines appear promising in terms of
efﬁcacy,many outstanding issues have beenhighlighted by recent trials,
such as the need to deﬁne a standardized protocol and tominimize cost
and time required for such treatments [65].
4. Future areas of study
As angiogenesis is a crucial part in the growth and maintenance
of tumors [68], one of the major areas of research is the search foranti-angiogenesis, not only for oncology but also inﬂammatory
and metabolic diseases where new vascularization is implicated in
pathology. As previously stated, Cathepsin S offers an enticing target
for such treatments.
Experiments have shown that the cartilage of rabbit and calf inhibits
tumor angiogenesis. From those observations, attention has turned to
cartilaginous ﬁsh, such as the shark, for a ready source of cartilage,
hoping that it that may lead to a new answer in the inhibition of
tumor angiogenesis [69]. Studies into the use of shark cartilage as a
tumor anti-angiogenesis solution have not been conclusive [70], how-
ever, certain elements of the shark's adaptive immune systemmay pro-
vide possible avenues of treatment.
Sharks possess an antibody isotype, IgNAR,which is characterized as
being a homodimer of IgH chains that do not use IgL chains. A domain
sharing high identity to IgNAR was discovered at the amino terminus
of T-cell Receptor δ [71]. This NAR-TCR variable domain is expressed
in addition to the canonical TCRδV domain. Furthermore, the NAR-TCR
δ chain contains two variable domains, both the product of V(D)J
genetic rearrangement. This allows both B and T cells of cartilaginous
ﬁsh to have the ability of making diverse repertoires of antigen
receptors that recognize antigenwith a projecting, free variable domain,
as opposed to the more planar paratope of traditional heterodimeric
receptors [69].
Contributing to the appeal of using shark IgNAR, is the ability to
develop therapeutic binders that recognize epitope recesses and may
not be accessible to the ﬂatter paratope of IgH + IgL antibodies.
Stability, tissue penetrance, B cell source, relatively simple single bind-
ing domain and the small size of shark IgNAR antibodies present attrac-
tive features that are being researched, both in academic and industrial
laboratories worldwide, to be exploited by immunotherapy [69].
These antibodies have demonstrated potencywhich is equivalent or
superior to that of their monospeﬁcic IgG counerparts [8]. However,
they still possess some clinical limitations that require further improve-
ments, namely short half-lives and possible toxicity due to concurrent T
cell co-stimulation [8,72].
A new format of bispeciﬁc antibodies are Bispeciﬁc T-cell engager
(BiTE) molecules, which target both CD3 and another antigenic marker.
These molecules show enhanced tumor cell lysis, high protein stability
and efﬁcacy at low T-cell/target ratios. BiTE antibodies may contribute
to cancer immunotherapy by redirecting the vast number of existing
T-cell clones in patients, while ignoring many of the immune escape
mechanisms that otherwise limit the speciﬁc anti-tumor responses of
T-cell clones [7].
Accumulating evidence suggests the existence of a subpopulation of
tumor cells with distinct stem-like properties being responsible for
tumor initiation, invasive growth and metastasis formation. Bispeciﬁc
antibodies, capable of targeting both cancer stem cells as well as tumor
antigens may prove to be effecting in eradicating said tumors, while
limiting their reincidence [73]. A study reported the effectiveness of this
therapy on cancer stem cells with a bispeciﬁc antibody against a variant
form of the epidermal growth factor receptor (EGFRvIII) and CD133.
Anti-EGFRvIII/CD133 mAb reduced the tumorigenicity of glioblastoma
cells better than any reagent directed against a single epitope [74].
Researchers have also been looking intoways to alter themagnitude
and quality of innate immune responses, induced by ADCC, in order to
improve the ensuing adaptive immune response. The Fc receptors for
IgG (FcγR) provide the key link between therapeutic antibodies and
the cellular immune system, enabling monoclonal antibodies to induce
adaptive immune responses. ADCC-based combination therapy can be
used to promote antigen presentation, co-stimulation and T-cell activa-
tion or expansion. Antibody structures can also be modiﬁed to selective
engage activating rather than inhibitory FcγR. The development of
fusion antibodies also shows promise. Fusion antibodies possess
immunostimulatory motifs, which can induce antigen presentation
and amplify co-stimulation, resulting in a more efﬁcient imune re-
sponse [72,75–77].
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It is quite clear that cancer immunotherapy has a bright future.
The amount ofwork and research that is being put into the discovery
of new targets and treatments leaves us hopeful that a signiﬁcant break-
through might still be achieved during our lifetime. Immunotherapy
presents opportunities to limit and eliminate tumor growth that simple
chemotherapy has not been able to achieve. The extent and speciﬁcity of
immunotherapy translate to quicker, better results without most of the
undesirable side-effects.
While the number of available therapies keeps growing and the pos-
sibilities are truly exciting, it seemsquite clear that theuse of antibodies,
especially monoclonal antibodies, is a truly promising path for the ﬁght
against cancer.
Monoclonal antibodies are supremely speciﬁc to their targets and
have a relatively short lifespan inside the organism. This limits the un-
desirable side effects, while potentiating the anti-cancer capabilities of
the therapy. Unfortunately, while this means that monoclonal antibody
immunotherapy is considerably safer than other forms of anti-cancer
therapy – namely small molecules – it is precisely due to their short
lifespan that the efﬁcacy of the treatment is limited.
This drawback might be overcome through the use of two simulta-
neous therapies, such as monoclonal antibodies paired up with chemo-
therapy. It is our hope that the shift might move away from the
damaging effects of the latter on the patient; as it also attacks healthy
cells, and onto the more paciﬁc results of the former.
Immunotherapy as a medical research ﬁeld continues to grow at an
exciting pace, with new options and hypothesis being introduced as
cancer biology becomes better understood. It is for these reasons that
we look forward to more advances in the ﬁeld, as well as to providing
our own contribution in the ﬁght against cancer.
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